

Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: A case report

YUKI IKEDA¹, Michihiro Ono¹, Ginji Omori¹, Saki Ameda¹, Michiko Yamada¹, Tomoyuki Abe¹, Shigeyuki Fujii¹, Miri Fujita¹, and Masahiro Maeda¹

¹Shinnittetsu Muroran Sogo Byoin

January 29, 2021

Abstract

Pembrolizumab is considered to be an effective therapy for patients with microsatellite instability (MSI)-high cancer. Here, we report a case of MSI-high cholangiocarcinoma effectively treated with pembrolizumab. MSI status should be actively evaluated in patients with cholangiocarcinoma.

Hosted file

main document ver.2.pdf available at <https://authorea.com/users/392592/articles/506396-successful-pembrolizumab-treatment-of-microsatellite-instability-high-intrahepatic-cholangiocarcinoma-a-case-report>

Hosted file

Figure ver.1.pptx available at <https://authorea.com/users/392592/articles/506396-successful-pembrolizumab-treatment-of-microsatellite-instability-high-intrahepatic-cholangiocarcinoma-a-case-report>